The use of a small, synthetic VDAC1‐antagonist peptide, derived from hexokinase, restores mitochondrial functionality, and respiration in cellular models of Alzheimer's disease. Here, VDAC1 is linked to early-onset autosomal dominant Alzheimer disease.